- Home
- GTIM vs BLRX Comparison
GTIM vs BLRX Comparison
Compare GTIM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTIM | BLRX |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 12.6M |
| IPO Year | 2013 | 2010 |
Fundamental Metrics
Financial Performance| Metric | GTIM | BLRX |
|---|---|---|
| Price | $1.37 | $2.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 28.3K | 10.2K |
| Earning Date | 05-07-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $142,315,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $46.00 | ★ N/A |
| Revenue Growth | ★ 3.01 | N/A |
| 52 Week Low | $1.10 | $2.15 |
| 52 Week High | $2.09 | $4.56 |
Technical Indicators
Market Signals| Indicator | GTIM | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 39.10 |
| Support Level | $1.36 | $2.65 |
| Resistance Level | $1.41 | $2.76 |
| Average True Range (ATR) | 0.04 | 0.16 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 34.44 | 17.84 |
Price Performance
Historical ComparisonAbout GTIM Good Times Restaurants Inc.
Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants, which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants, which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers, chicken, frozen custard; slides and drinks.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.